产品活性： Trastuzumab deruxtecan (T-DXd; DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-活性分子偶联物 (ADC)。Trastuzumab deruxtecan 由人源化抗 HER2 ...

The Toxicities and Adverse Effects That Emergency Physicians Must Know,” published in the December 2024 issue of Emeregency ...

Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.

Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...

A University of Liverpool study reveals how two critical molecules present in 'HER2-positive' breast cancer - one of the most ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

SHR-A1811 showed promising antitumor activity and acceptable tolerability in patients with HER2-positive breast cancer, ...

The efficacy of trastuzumab deruxtecan after endocrine-based therapy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 is unknown.

The successful entry of HANQUYOU into the U.S. market not only expands our international footprint but also lays a solid foundation for the globalization of our other products. Since the commercial ...

Background: Trastuzumab therapy for HER2-positive cancers is associated with cardiotoxicity. This umbrella review synthesizes evidence from systematic reviews and meta-analyses on cardioprotective ...

A breast cancer drug - which keeps the disease stable for up to four times longer than the previous treatment - will be ...

台康生技(6589)今(10)日公告乳癌生物相似药EG12014(Trastuzumab Biosimilar, also called EGI2014)FDA药证申覆未通过，查厂结果充填厂仍需改善。台康生技今日股价开盘直接锁在跌停板82.9元，至10:40，超过2800张的卖 ...